Fig. 10From: Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinomaEvaluation of tumor mutation burden and the response to immunotherapy among high- and low-risk groups. A Mutation profiles of high- and low-risk groups. B The relationship between CMGs risk signature and TMB. C The association between IPS and risk signature for HCC patientsBack to article page